The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma

Acta Oto-Laryngologica

Volumn 126, Issue 7, 2006, Pages 769-774

  Wang, Ling Feng ^a   Chai, Chee Yin ^a,c   Kuo, Wen Rei ^a,b   Tai, Chih Feng ^a,b   Lee, Ka Wo ^a,b   Ho, Kuen Yao ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Immunohistochemistry; Nasopharyngeal carcinoma; p53 protein; Proliferating cell nuclear antigen (PCNA)

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745684526     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480500469545     Document Type: Article

References (26)

1. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
2. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, et al. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996;2:1591-9.
3. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 1997;3:1195-200.
4. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-59.
5. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-60.
6. Thomas H, Nasim MM, Sarraf CE, Alison MR, Love S, Lambert HE, et al. Proliferating cell nuclear antigen (PCNA) immunostaining - a prognostic factor in ovarian cancer? Br J Cancer 1995;71:357-62.
7. Jain S, Filipe MI, Hall PA, Waseem N, Lane DP, Levisin DA. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991;44:655-9.
8. Chan AT, Ho S, Teo PM, Tjong J, Choi J, Lee WY, et al. Assessment of proliferating cell nuclear antigen in nasopharyngeal carcinoma tissue and its relation to clinical findings. Oral Oncol 1997;33:13-8.
9. Genc E, Hosal AS, Gedikoglu G, Ozyar E, Sozeri B. Prognostic value of p53, proliferating cell nuclear antigen, and Ki-67 expression in undifferentiated nasopharyngeal carcinomas. Otolaryngol Head Neck Surg 2000;122:868-73.
10. Tsai ST, Jin YT, Leung HW, Wang ST, Tsao CJ, Su IJ. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res 1998;18:2849-54.
11. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.
12. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-7.
13. Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998;83:582-8.
14. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst 1993;85:971-8.
15. Kouvidou C, Stefanaki K, Dai Y, Tzardi M, Koutsoubi K, Darivianaki K, et al. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. Anticancer Res 1997;17:2615-9.
16. Niemhom S, Kitazawa S, Murao S, Kunachak S, Maeda S. Co-expression of p53 and bcl-2 may correlate to the presence of Epstein-Barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma. Cancer Lett 2000;160:199-208.
17. Hall PA, Coates PJ, Goodlad RA, Hart IR, Lane DP. Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo. Br J Cancer 1994;70:244-7.
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
19. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-6.
20. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
21. Faccioli S, Cavicchi O, Caliceti U, Rinaldi Ceroni A, Chieco P. Cell proliferation as an independent predictor of survival for patients with advanced nasopharyngeal carcinoma. Mod Pathol 1997;10:884-94.
22. Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O'Sullivan B, et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002;94:1997-2006.
23. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 2003;25:864-72.
24. Masuda M, Shinokuma A, Hirakawa N, Nakashima T, Komiyama S. Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 1998;20:640-4.
25. Ho KY, Kuo WR, Chai CY, Tsai SM, Sheu SH, Wu SC, , et al. A prospective study of p53 expression and its correlation with clinical response of radiotherapy in nasopharyngeal carcinoma. Laryngoscope 2001;111:131-6.
26. Sheu LF, Chen A, Tseng HH, Leu FJ, Lin JK, Ho KC, et al. Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol 1995;26:380-6.